GlaxoSmithKline has no plans to delist Indian arm - executive
MUMBAI (Reuters) - GlaxoSmithKline Plc has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare Ltd, David Redfern, chief strategy officer at Britain's biggest drugmaker, said on Monday.
GSK said earlier it planned to buy up to an additional 31.8 percent stake in the Indian unit for 52.2 billion rupees ($939 million).
The company has been expanding into both emerging markets and non-prescription consumer health - and in some cases a combination of the two.
The company, which plans to launch new variants of the flagship Horlicks brand in India, is looking to increase penetration of the product in the north and western regions of the country, Redfern said.
(Reporting by Kaustubh Kulkarni; Editing by Subhranshu Sahu)
Thousands line up to say goodbye to Nelson Mandela, whose body is lying in state in Pretoria. Slideshow
LONDON - Global equities headed for their biggest two-week drop since June and the dollar hit 5-year highs against the yen on Friday amid concern the U.S. Federal Reserve could start scaling back its stimulus as early as next week.
WASHINGTON - U.S. small business sentiment bounced back from a seven-month low in November, with owners setting their sights on creating more jobs and expanding operations.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.